Rankings
▼
Calendar
DFTX Q3 2024 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
DFTX
Definium Therapeutics, Inc.
$2B
Q3 2024 Earnings
Healthcare
Medical - Pharmaceuticals
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$25M
Net Income
-$14M
EPS (Diluted)
$-0.17
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$17M
Free Cash Flow
-$17M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$320M
Total Liabilities
$58M
Stockholders' Equity
$262M
Cash & Equivalents
$295M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$25M
-$22M
-14.7%
Net Income
-$14M
-$18M
+23.7%
← FY 2024
All Quarters
Q4 2024 →